|
Re: Zenith trial partners
|
3
|
Zenith Epigenetics
|
Feb 01, 2023 09:11PM
|
|
Re: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
|
10
|
Resverlogix Corp.
|
Mar 17, 2022 07:58PM
|
|
Re: https://themarkether...
|
4
|
Resverlogix Corp.
|
Feb 22, 2022 10:28PM
|
|
Re: https://themarkether...
|
6
|
Resverlogix Corp.
|
Feb 22, 2022 09:32PM
|
|
Re: Calgary-developed COVID-19 drug begins trials in local hospitals and Brazil.
|
4
|
Resverlogix Corp.
|
Feb 21, 2022 12:15AM
|
|
Re: No change in Ottawa.
|
3
|
Resverlogix Corp.
|
Sep 21, 2021 11:28PM
|
|
Re: Thoughts on ZCC
|
2
|
Zenith Epigenetics
|
Sep 13, 2021 10:12PM
|
|
Re: Eversana.
|
4
|
Resverlogix Corp.
|
Jun 03, 2021 08:49PM
|
|
Re: Actual salaries paid
|
5
|
Resverlogix Corp.
|
May 22, 2021 07:20PM
|
|
Re: Quick Hits
|
3
|
Resverlogix Corp.
|
Mar 12, 2021 07:30PM
|
|
Re: from J4P on SH , "I will go out on a limb with a prediction..." Good, Better, Best and Share price
|
4
|
Resverlogix Corp.
|
Mar 06, 2021 10:51PM
|
|
Re: Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
|
7
|
Resverlogix Corp.
|
Mar 03, 2021 07:37PM
|
|
Re: Question
|
3
|
Resverlogix Corp.
|
Feb 24, 2021 04:30PM
|
|
Re: Question
|
2
|
Resverlogix Corp.
|
Feb 24, 2021 02:39PM
|
|
Resverlogix ad
|
1
|
Resverlogix Corp.
|
Jan 29, 2021 01:15PM
|
|
Re: everything r v x is down 4% to around 24%
|
|
Resverlogix Corp.
|
Jan 27, 2021 05:31PM
|
|
Re: Filled!
|
2
|
Zenith Epigenetics
|
Jan 22, 2021 11:15AM
|
|
Re: Filled!
|
1
|
Zenith Epigenetics
|
Jan 21, 2021 10:29PM
|
|
Re: Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
|
7
|
Resverlogix Corp.
|
Jan 12, 2021 08:58PM
|
|
Re: I think we would do way,
|
4
|
Resverlogix Corp.
|
Jan 12, 2021 03:47PM
|
